The present disclosure discloses a method for preparing an anti-hepatoma drug sanjie tablet, which includes a sanjie tablet containing components of Typhonii Rhizoma, exocarp of Juglans mandshurica, Dictamni Cortex and Bovis Calculus Artifactus. The preparation method includes the steps of: step 1. removing toxins from the components of Typhonii Rhizoma, exocarp of Juglans mandshurica and Dictamni Cortex in the sanjie tablet to obtain powder of nontoxic Typhonii Rhizoma, nontoxic exocarp of Juglans mandshurica, and nontoxic Dictamni Cortex; and step 2, uniformly mixing the powder of nontoxic Typhonii Rhizoma, nontoxic exocarp of Juglans mandshurica, and nontoxic Dictamni Cortex obtained in step 1 with Bovis Calculus Artifactus, granulating with a volatile medium, drying, tabletting, and conducting film-coating to obtain the sanjie tablet. Beneficial effects: the components in the composition of the sanjie tablet is decomposed and transformed by probiotics, and improving the medication safety of a patient in clinic.

The present disclosure discloses a method for preparing an anti-hepatoma drug sanjie tablet, which includes a sanjie tablet containing components of Typhonii Rhizoma, exocarp of Juglans mandshurica, Dictamni Cortex and Bovis Calculus Artifactus. The preparation method includes the steps of: step 1. removing toxins from the components of Typhonii Rhizoma, exocarp of Juglans mandshurica and Dictamni Cortex in the sanjie tablet to obtain powder of nontoxic Typhonii Rhizoma, nontoxic exocarp of Juglans mandshurica, and nontoxic Dictamni Cortex; and step 2, uniformly mixing the powder of nontoxic Typhonii Rhizoma, nontoxic exocarp of Juglans mandshurica, and nontoxic Dictamni Cortex obtained in step 1 with Bovis Calculus Artifactus, granulating with a volatile medium, drying, tabletting, and conducting film-coating to obtain the sanjie tablet. Beneficial effects: the components in the composition of the sanjie tablet is decomposed and transformed by probiotics, and improving the medication safety of a patient in clinic.

An application of a traditional Chinese medicine composition in preparing a medicine for treating or preventing coronavirus infection. The traditional Chinese medicine composition is characterized by being prepared from the following raw materials in parts by weight: 5-15 parts of Cornu saigae tataricae or 50-150 parts of goral horns, 10-60 parts of Bulbus Fritillariae Ussuriensis, 15-60 parts of Radix et Rhizoma Rhei, 7-30 parts of Radix scutellariae, 7-30 parts of Lapis Chloriti, 10-50 parts of gypsum fibrosum, 5-20 parts of calculus bovis artifactus, and 15-60 parts of radix glycyrrhizae. The traditional Chinese medicine composition can inhibit 2019-nCoV replication in cells, so that cells infected by 2019-nCoV viruses have no lesion. Therefore, the traditional Chinese medicine composition can treat or prevent coronavirus related diseases.

An application of a traditional Chinese medicine composition in preparing a medicine for treating or preventing coronavirus infection. The traditional Chinese medicine composition is characterized by being prepared from the following raw materials in parts by weight: 5-15 parts of Cornu saigae tataricae or 50-150 parts of goral horns, 10-60 parts of Bulbus Fritillariae Ussuriensis, 15-60 parts of Radix et Rhizoma Rhei, 7-30 parts of Radix scutellariae, 7-30 parts of Lapis Chloriti, 10-50 parts of gypsum fibrosum, 5-20 parts of calculus bovis artifactus, and 15-60 parts of radix glycyrrhizae. The traditional Chinese medicine composition can inhibit 2019-nCoV replication in cells, so that cells infected by 2019-nCoV viruses have no lesion. Therefore, the traditional Chinese medicine composition can treat or prevent coronavirus related diseases.

Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.

Provided herein are methods of making and using a number of different types of liver cells.

Provided herein are methods of making and using a number of different types of liver cells.

Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.

Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.